Background: In the United States, genotype 2 accounts for approximately 13 to 15% of all hepatitis C infections. Given the relatively high sustained virologic response (SVR) rates with the treatment of genotype 2 historically, the data regarding retreatment of patients with genotype 2 in whom prior therapy failed is somewhat limited. The following discussion regarding initial treatment and retreatment of patients with genotype 2 chronic hepatitis C assumes the patient and their clinician have already made the decision to proceed with hepatitis C therapy. For the regimens included as preferred or alternative in the 2016 American Association for the Study of Liver Diseases and Infectious Diseases Society of America (AASLD/IDSA) guidance for genotype 2 infection, the cost of the preferred and alternative treatment regimens, when including initial treatment and retreatment, range from approximately $75,000 to $294,000 (Figure 1). Although some company-related drug assistance programs provide free medication to certain low-income patients, getting medications paid for remains problematic for many clinicians and patients.
Medications Used to Treat HCV: The HCV Medications section on this web site provides detailed information for each of the FDA-approved medications listed in the treatment recommendations, including links to the full prescribing information and to patient assistance programs. Adherence with the treatment regimen is of paramount importance. Accordingly, patients should receive detailed counseling regarding the importance of adherence prior to starting therapy and clinicians should provide intensive follow-up during therapy.